|
|
|
|
|
|
|
|
abstract
Highlights
- •
- Genomic instability and angiogenesis appear as the cornerstone in molecularly-driven therapy in high-grade serous OC.
- •
- Targeting sustained proliferative signaling seems the most promising approach for low-grade and clear cell OC.
- •
- Evasion of immune destruction is the emerging target in high-grade serous OC.
Objective
As
a result of relevant achievements in the field of translational
research, several active drugs and multiple biological targets are
available in ovarian cancer (OC). In this complex scenario, there is an
urgent need to effectively summarize the available data in order to
update conclusions, and outline perspectives.
Methods
The
results in terms of target identification and drug development have
been summarized using the well-known hallmarks of cancer firstly
described, and recently modified by Hanahan and Weinberg [1–2].
Published data from clinical trials have been retrieved from PubMed,
Embase, CINAHL and Cochrane database. Ongoing clinical trials were
searched using clinicaltrials.gov web platform, and identified using NCT number.
Results
Genomic
instability and angiogenesis are the most actively investigated
hallmarks in high-grade serous OC, and the inhibition of tumor immune
evasion appears as the emerging strategy for molecularly-driven therapy.
Targeting sustained proliferative signaling through MEK and mTOR
inhibitors seems the most promising approach in clear cell, and
low-grade serous OC.
Conclusions
This
substantial amount of data suggests that targeted therapies are already
part of the clinical and therapeutic management of OC patients. The
expectations of getting from translational research a better knowledge
of tumor biology and therefore personalized drugs are high and worthy of
maximum effort from referral centers.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.